Trustees overseeing two exchange-traded funds recently launched by startup asset management firm Azoria Capital LLC said they have voted to liquidate and terminate both the Azoria 500 Meritocracy ETF ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

“We often see distinct factors become more correlated for short periods, amplifying losses across what an investor previously ...

Nedgroup Investment's chief commercial officer shares her thoughts on asset classes, strategies and working with clients over ...

For the first time in a long time, Williams believes in his health. He and the Bulls are hoping it pays dividends for the ...

Circle's business is highly dependent on interest income on reserves, which could drop significantly in the event of macro ...

Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene ...

In conversations over tea and spreadsheets alike, one phrase keeps surfacing in India’s real estate circles, branded ...

Security experts say the greatest number of ransomware attacks in recent months has continued to trace to the long-running ...

Roberts Bakery has been saved from going under by the private investment vehicle of UK-based billionaire Ranjit Singh Boparan ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.